Literature DB >> 30830861

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection.

Li Liu1,2, Qiang Wei3, Qingqing Lin1, Jun Fang1, Haibo Wang1, Hauyee Kwok1, Hangying Tang1, Kenji Nishiura1, Jie Peng1, Zhiwu Tan1, Tongjin Wu1, Ka-Wai Cheung1, Kwok-Hung Chan1, Xavier Alvarez4, Chuan Qin3, Andrew Lackner4, Stanley Perlman5,6, Kwok-Yung Yuen1, Zhiwei Chen1,2.   

Abstract

Newly emerging viruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle Eastern respiratory syndrome CoVs (MERS-CoV), and H7N9, cause fatal acute lung injury (ALI) by driving hypercytokinemia and aggressive inflammation through mechanisms that remain elusive. In SARS-CoV/macaque models, we determined that anti-spike IgG (S-IgG), in productively infected lungs, causes severe ALI by skewing inflammation-resolving response. Alveolar macrophages underwent functional polarization in acutely infected macaques, demonstrating simultaneously both proinflammatory and wound-healing characteristics. The presence of S-IgG prior to viral clearance, however, abrogated wound-healing responses and promoted MCP1 and IL-8 production and proinflammatory monocyte/macrophage recruitment and accumulation. Critically, patients who eventually died of SARS (hereafter referred to as deceased patients) displayed similarly accumulated pulmonary proinflammatory, absence of wound-healing macrophages, and faster neutralizing antibody responses. Their sera enhanced SARS-CoV-induced MCP1 and IL-8 production by human monocyte-derived wound-healing macrophages, whereas blockade of FcγR reduced such effects. Our findings reveal a mechanism responsible for virus-mediated ALI, define a pathological consequence of viral specific antibody response, and provide a potential target for treatment of SARS-CoV or other virus-mediated lung injury.

Entities:  

Keywords:  Cytokines; Immunoglobulins; Infectious disease; Macrophages; Pulmonology

Year:  2019        PMID: 30830861      PMCID: PMC6478436          DOI: 10.1172/jci.insight.123158

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  52 in total

1.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.

Authors:  R Atreya; J Mudter; S Finotto; J Müllberg; T Jostock; S Wirtz; M Schütz; B Bartsch; M Holtmann; C Becker; D Strand; J Czaja; J F Schlaak; H A Lehr; F Autschbach; G Schürmann; N Nishimoto; K Yoshizaki; H Ito; T Kishimoto; P R Galle; S Rose-John; M F Neurath
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

Review 2.  Macrophages in Tissue Repair, Regeneration, and Fibrosis.

Authors:  Thomas A Wynn; Kevin M Vannella
Journal:  Immunity       Date:  2016-03-15       Impact factor: 31.745

3.  T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice.

Authors:  Jincun Zhao; Jingxian Zhao; Stanley Perlman
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

Review 4.  Immune responses and disease enhancement during respiratory syncytial virus infection.

Authors:  Peter J M Openshaw; John S Tregoning
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

5.  Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.

Authors:  Lanying Du; Guangyu Zhao; Yongping Lin; Hongyan Sui; Chris Chan; Selene Ma; Yuxian He; Shibo Jiang; Changyou Wu; Kwok-Yung Yuen; Dong-Yan Jin; Yusen Zhou; Bo-Jian Zheng
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

6.  Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.

Authors:  Jens H W Pahl; Kitty M C Kwappenberg; Eleni M Varypataki; Susy J Santos; Marieke L Kuijjer; Susan Mohamed; Juul T Wijnen; Maarten J D van Tol; Anne-Marie Cleton-Jansen; R Maarten Egeler; Wim Jiskoot; Arjan C Lankester; Marco W Schilham
Journal:  J Exp Clin Cancer Res       Date:  2014-03-10

7.  Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys.

Authors:  Jun Zhou; Wei Wang; Qiong Zhong; Wei Hou; Zhanqiu Yang; Shu-Yuan Xiao; Runqing Zhu; Zhijiao Tang; Yong Wang; Qiaoyang Xian; Hongbing Tang; Li Wen
Journal:  Vaccine       Date:  2005-05-02       Impact factor: 3.641

8.  Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.

Authors:  Ede Qin; Huiying Shi; Lin Tang; Cuie Wang; Guohui Chang; Zhifen Ding; Kai Zhao; Jian Wang; Ze Chen; Man Yu; Bingyin Si; Jianyuan Liu; Donglai Wu; Xiaojie Cheng; Baoan Yang; Wenming Peng; Qingwen Meng; Bohua Liu; Weiguo Han; Xunnan Yin; Hongyuan Duan; Dawei Zhan; Long Tian; Shuangli Li; Jinsong Wu; Gang Tan; Yi Li; Yuchuan Li; Yonggang Liu; Hong Liu; Fushuang Lv; Yu Zhang; Xiangang Kong; Baochang Fan; Tao Jiang; Shuli Xu; Xiaomei Wang; Changwen Li; Xiaohong Wu; Yongqiang Deng; Min Zhao; Qingyu Zhu
Journal:  Vaccine       Date:  2005-09-12       Impact factor: 3.641

9.  Macrophage activation and polarization: nomenclature and experimental guidelines.

Authors:  Peter J Murray; Judith E Allen; Subhra K Biswas; Edward A Fisher; Derek W Gilroy; Sergij Goerdt; Siamon Gordon; John A Hamilton; Lionel B Ivashkiv; Toby Lawrence; Massimo Locati; Alberto Mantovani; Fernando O Martinez; Jean-Louis Mege; David M Mosser; Gioacchino Natoli; Jeroen P Saeij; Joachim L Schultze; Kari Ann Shirey; Antonio Sica; Jill Suttles; Irina Udalova; Jo A van Ginderachter; Stefanie N Vogel; Thomas A Wynn
Journal:  Immunity       Date:  2014-07-17       Impact factor: 31.745

10.  A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice.

Authors:  Zhi-Yong Yang; Wing-Pui Kong; Yue Huang; Anjeanette Roberts; Brian R Murphy; Kanta Subbarao; Gary J Nabel
Journal:  Nature       Date:  2004-04-01       Impact factor: 49.962

View more
  329 in total

1.  Promise and challenges in the development of COVID-19 vaccines.

Authors:  Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2020-07-23       Impact factor: 3.452

Review 2.  Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review.

Authors:  Esteban Ortiz-Prado; Katherine Simbaña-Rivera; Lenin Gómez-Barreno; Mario Rubio-Neira; Linda P Guaman; Nikolaos C Kyriakidis; Claire Muslin; Ana María Gómez Jaramillo; Carlos Barba-Ostria; Doménica Cevallos-Robalino; Hugo Sanches-SanMiguel; Luis Unigarro; Rasa Zalakeviciute; Naomi Gadian; Andrés López-Cortés
Journal:  Diagn Microbiol Infect Dis       Date:  2020-05-30       Impact factor: 2.803

Review 3.  COVID-19: The Emerging Immunopathological Determinants for Recovery or Death.

Authors:  Tanveer Ahmad; Rituparna Chaudhuri; Mohan C Joshi; Ahmad Almatroudi; Arshad Husain Rahmani; Syed Mansoor Ali
Journal:  Front Microbiol       Date:  2020-12-01       Impact factor: 5.640

4.  Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.

Authors:  Mohamad Hesam Shahrajabian; Wenli Sun; Qi Cheng
Journal:  Hum Vaccin Immunother       Date:  2020-08-12       Impact factor: 3.452

5.  A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus.

Authors:  Bronwyn M Gunn; Richard Lu; Matthew D Slein; Philipp A Ilinykh; Kai Huang; Caroline Atyeo; Sharon L Schendel; Jiyoung Kim; Caitlin Cain; Vicky Roy; Todd J Suscovich; Ayato Takada; Peter J Halfmann; Yoshihiro Kawaoka; Matthias G Pauthner; Mambu Momoh; Augustine Goba; Lansana Kanneh; Kristian G Andersen; John S Schieffelin; Donald Grant; Robert F Garry; Erica Ollmann Saphire; Alexander Bukreyev; Galit Alter
Journal:  Immunity       Date:  2021-04-13       Impact factor: 31.745

6.  Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.

Authors:  Xiaojie Wu; Nanyang Li; Guoqin Wang; Wei Liu; Jicheng Yu; Guoying Cao; Jingjing Wang; Yuancheng Chen; Juan Ma; Jufang Wu; Haijing Yang; Xiaomeng Mao; Jinjie He; Yiqi Yu; Chao Qiu; Ning Li; Sheng Yao; Hui Feng; Jinghua Yan; Wenhong Zhang; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

Review 7.  Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2.

Authors:  Ian McDonald; Sam M Murray; Catherine J Reynolds; Daniel M Altmann; Rosemary J Boyton
Journal:  NPJ Vaccines       Date:  2021-05-13       Impact factor: 7.344

Review 8.  The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).

Authors:  Narasimha M Beeraka; SubbaRao V Tulimilli; Medha Karnik; Surya P Sadhu; Rajeswara Rao Pragada; Gjumrakch Aliev; SubbaRao V Madhunapantula
Journal:  Biomed Res Int       Date:  2021-06-01       Impact factor: 3.411

9.  A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens.

Authors:  Ebony N Gary; Bryce M Warner; Elizabeth M Parzych; Bryan D Griffin; Xizhou Zhu; Nikesh Tailor; Nicholas J Tursi; Mable Chan; Mansi Purwar; Robert Vendramelli; Jihae Choi; Kathy L Frost; Sophia Reeder; Kevin Liaw; Edgar Tello; Ali R Ali; Kun Yun; Yanlong Pei; Sylvia P Thomas; Amira D Rghei; Matthew M Guilleman; Kar Muthumani; Trevor Smith; Sarah K Wootton; Ami Patel; David B Weiner; Darwyn Kobasa
Journal:  iScience       Date:  2021-06-08

Review 10.  Physiological and Pathological Inflammation Induced by Antibodies and Pentraxins.

Authors:  Chiara Elisabeth Geyer; Lynn Mes; Melissa Newling; Jeroen den Dunnen; Willianne Hoepel
Journal:  Cells       Date:  2021-05-12       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.